期刊
CURRENT ONCOLOGY
卷 30, 期 5, 页码 4603-4617出版社
MDPI
DOI: 10.3390/curroncol30050348
关键词
multiple myeloma; neoantigens; conjugated-drug antibodies; bispecific antibodies; trispecific antibodies; CAR-T cells
类别
Multiple myeloma (MM) is a difficult-to-treat malignant disease characterized by the proliferation of plasma cells in the bone marrow. This review analyzes the presence of neoantigens in MM patients and evaluates their potential as prognostic factors or therapeutic targets. The use of neoantigen treatment strategies and bispecific, trispecific, and conjugated antibodies for MM treatment are discussed. The utilization of CAR-T in relapsed and refractory patients is also examined.
Multiple myeloma (MM) is malignant disease characterized by the clonal proliferation of plasma cells in the bone marrow, leading to anemia, immunosuppression, and other symptoms, that is generally hard to treat. In MM, the immune system is likely exposed to neoplasia-associated neoantigens for several years before the tumor onset. Different types of neoantigens have been identified. Public or shared neoantigens derive from tumor-specific modifications often reported in several patients or across diverse tumors. They are intriguing therapeutic targets because they are frequently observed, and they have an oncogenic effect. Only a small number of public neoantigens have been recognized. Most of the neoantigens that have been identified are patient-specific or private, necessitating a personalized approach for adaptive cell treatment. It was demonstrated that the targeting of a single greatly immunogenic neoantigen may be appropriate for tumor control. The purpose of this review was to analyze the neoantigens present in patients with MM, and to evaluate the possibility of using their presence as a prognostic factor or as a therapeutic target. We reviewed the most recent literature on neoantigen treatment strategies and on the use of bispecific, trispecific, and conjugated antibodies for the treatment of MM. Finally, a section was dedicated to the use of CAR-T in relapsed and refractory patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据